By Dr Leena Yadav
REPRODUCTIVE GENETICS
ERA - Personalised Embryo Transfer / CGT Carrier Genetic Test
CGT is an important test when planning a family , because it helps to determine the risk of having a child with a genetic disorder.
It identifies a person or a couple which are carriers of a particular disorder. A positive result indicates the presence of one or more mutations in the person. In such a case , the test should be carried out in the other member of the couple. If both partners carry a mutation in the same gene , they will be at high risk of having an affected child . One should opt for a CGT test before an assisted reproductive treatment like IVF , etc or before planning a baby with donor sperm or eggs or before attempting pregnancy by natural means.
It evaluates disorders like Cystic Fibrosis , Beta Thalassemia , Sickle Cell Disease , Spinal Muscular Atrophy , Haemophilia Type A and etc. CGT helps prevent disorders which can't be cured.
Simple blood sample from each partner is required and the results are obtained within 30 working days.
Anyone , without knowing, can be a carrier of one or more mutations. Being a parent carrying a mutation doesn't mean you'll develop the illness , but if both parents are carrier of a mutation in same gene , the probability of having an affected child is 25%.
A simple blood test for parents prior to pregnancy can help prevent genetic disorders in the child to be born.
ERA test indicates the best day for your embryo to be transferred , increasing your chances of successful pregnancy. The Endometrial Receptivity Analysis is an Endometrial evaluation test and a diagnostic tool which allows to analyse the level of expression of 238 genes related with the status of Endometrial Receptivity. It helps us to find a personalized window of implantation for each patient before the patient starts using assisted reproduction techniques.
The Era Test is recommended by the clinician in patients who have experienced implantation failures with good quality embryos ( at least 3 implantation failures in young women or 2 in patients 37 yrs old or more ) . It is indicated for patients with an apparently normal uterus and with an endometrium with a normal thickness of 6 mm or more.
The ERA test is a transcriptomic analysis of 238 genes that conform the signature of Endometrial Receptivity and hence identifies the patients personalized window of implantation.